Which has preferable valuation & earnings, ERAS or SVRA?

Erasca is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is ERAS or SVRA more profitable?

Erasca's return on equity of -35.31% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Savara N/A -87.19% -66.42%

Does the media favor ERAS or SVRA?

In the previous week, Erasca had 33 more articles in the media than Savara. MarketBeat recorded 35 mentions for Erasca and 2 mentions for Savara. Savara's average media sentiment score of 0.00 beat Erasca's score of -0.15 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 29 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SVRA or MANE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Veradermics N/A N/A N/A N/A N/A

Is SVRA or MANE more profitable?

Veradermics' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Veradermics N/A N/A N/A

Does the media refer more to SVRA or MANE?

In the previous week, Veradermics had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Savara. Veradermics' average media sentiment score of 0.54 beat Savara's score of 0.00 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Veradermics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SVRA or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is SVRA or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media prefer SVRA or EWTX?

In the previous week, Edgewise Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 2 mentions for Savara. Edgewise Therapeutics' average media sentiment score of 0.09 beat Savara's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Savara (SVRA) Competitors

$5.50 +0.12 (+2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$5.46 -0.04 (-0.82%)

As of 07:03 PM Eastern

Compare

SVRA vs. ERAS, MANE, EWTX, CPRX, and KNSA

Should you buy Savara stock or one of its competitors? MarketBeat compares Savara with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Savara include Erasca (ERAS), Veradermics (MANE), Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does Savara compare to Erasca?

Erasca (NASDAQ:ERAS) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Erasca has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Savara has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

In the previous week, Erasca had 33 more articles in the media than Savara. MarketBeat recorded 35 mentions for Erasca and 2 mentions for Savara. Savara's average media sentiment score of 0.00 beat Erasca's score of -0.15 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	29 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Erasca shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Erasca's return on equity of -35.31% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Savara	N/A	-87.19%	-66.42%

Erasca currently has a consensus price target of $20.11, indicating a potential upside of 47.12%. Savara has a consensus price target of $10.14, indicating a potential upside of 84.42%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Erasca is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Savara beats Erasca on 8 of the 14 factors compared between the two stocks.

How does Savara compare to Veradermics?

Savara (NASDAQ:SVRA) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Savara presently has a consensus price target of $10.14, indicating a potential upside of 84.42%. Veradermics has a consensus price target of $114.20, indicating a potential upside of 21.81%. Given Savara's stronger consensus rating and higher possible upside, equities analysts plainly believe Savara is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Veradermics had 1 more articles in the media than Savara. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Savara. Veradermics' average media sentiment score of 0.54 beat Savara's score of 0.00 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veradermics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Veradermics	N/A	N/A	N/A

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Summary

Savara beats Veradermics on 5 of the 9 factors compared between the two stocks.

How does Savara compare to Edgewise Therapeutics?

Savara (NASDAQ:SVRA) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Savara has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

87.9% of Savara shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Edgewise Therapeutics' return on equity of -32.55% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

In the previous week, Edgewise Therapeutics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 2 mentions for Savara. Edgewise Therapeutics' average media sentiment score of 0.09 beat Savara's score of 0.00 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Savara currently has a consensus target price of $10.14, indicating a potential upside of 84.42%. Edgewise Therapeutics has a consensus target price of $47.30, indicating a potential upside of 28.28%. Given Savara's stronger consensus rating and higher possible upside, research analysts clearly believe Savara is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Savara and Edgewise Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Savara compare to Catalyst Pharmaceuticals?

Savara (NASDAQ:SVRA) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

87.9% of Savara shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Savara had 2 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 2 mentions for Savara and 0 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.00 beat Savara's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Savara	Neutral
Catalyst Pharmaceuticals	Positive

Savara presently has a consensus target price of $10.14, suggesting a potential upside of 84.42%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.98%. Given Savara's stronger consensus rating and higher possible upside, research analysts plainly believe Savara is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Catalyst Pharmaceuticals	$588.99M	6.52	$214.33M	$1.74	18.03

Savara has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Savara's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summary

Catalyst Pharmaceuticals beats Savara on 11 of the 16 factors compared between the two stocks.

How does Savara compare to Kiniksa Pharmaceuticals International?

Savara (NASDAQ:SVRA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

87.9% of Savara shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Savara has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Savara currently has a consensus price target of $10.14, indicating a potential upside of 84.42%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 10.43%. Given Savara's higher probable upside, research analysts plainly believe Savara is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Savara's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than Savara. MarketBeat recorded 5 mentions for Kiniksa Pharmaceuticals International and 2 mentions for Savara. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Savara's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Kiniksa Pharmaceuticals International	$677.56M	6.26	$59.01M	$0.90	61.23

Summary

Kiniksa Pharmaceuticals International beats Savara on 12 of the 16 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.10B	$2.99B	$6.46B	$12.38B
Dividend Yield	N/A	1.78%	2.68%	5.68%
P/E Ratio	-9.82	13.11	20.73	22.36
Price / Sales	N/A	682.46	577.04	128.85
Price / Cash	N/A	56.55	44.20	55.24
Price / Book	5.50	4.04	10.70	6.58
Net Income	-$118.84M	$75.79M	$3.57B	$337.29M
7 Day Performance	4.36%	0.16%	0.56%	0.55%
1 Month Performance	12.02%	1.86%	3.57%	4.43%
1 Year Performance	165.70%	24.73%	28.49%	31.16%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	1.6793 of 5 stars	$5.50 +2.2%	$10.14 +84.4%	+163.7%	$1.10B	N/A	N/A	20	High Trading Volume
ERAS Erasca	2.237 of 5 stars	$12.87 +7.5%	$20.11 +56.3%	+924.2%	$4.00B	N/A	N/A	120	Trending News Gap Up
MANE Veradermics	N/A	$90.74 -1.0%	$109.00 +20.1%	N/A	$3.83B	N/A	N/A	19	Analyst Forecast Gap Up
EWTX Edgewise Therapeutics	2.6558 of 5 stars	$34.84 -2.1%	$44.22 +26.9%	+140.3%	$3.83B	N/A	N/A	60	Positive News Analyst Forecast
CPRX Catalyst Pharmaceuticals	3.5937 of 5 stars	$31.28 +0.0%	$32.00 +2.3%	+35.2%	$3.83B	$588.99M	17.98	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. ERAS, MANE, EWTX, CPRX, and KNSA

How does Savara compare to Erasca?

Summary

How does Savara compare to Veradermics?

Summary

How does Savara compare to Edgewise Therapeutics?

Summary

How does Savara compare to Catalyst Pharmaceuticals?

Summary

How does Savara compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. ERAS, MANE, EWTX, CPRX, and KNSA

How does Savara compare to Erasca?

Which has more volatility & risk, ERAS or SVRA?

Does the media favor ERAS or SVRA?

Do insiders and institutionals hold more shares of ERAS or SVRA?

Is ERAS or SVRA more profitable?

Do analysts prefer ERAS or SVRA?

Which has preferable valuation & earnings, ERAS or SVRA?

Summary

How does Savara compare to Veradermics?

Do analysts recommend SVRA or MANE?

Does the media refer more to SVRA or MANE?

Is SVRA or MANE more profitable?

Do insiders and institutionals believe in SVRA or MANE?

Which has better earnings and valuation, SVRA or MANE?

Summary

How does Savara compare to Edgewise Therapeutics?

Which has more risk & volatility, SVRA or EWTX?

Which has preferable earnings & valuation, SVRA or EWTX?

Do insiders and institutionals believe in SVRA or EWTX?

Is SVRA or EWTX more profitable?

Does the media prefer SVRA or EWTX?

Do analysts rate SVRA or EWTX?

Summary

How does Savara compare to Catalyst Pharmaceuticals?

Do insiders and institutionals hold more shares of SVRA or CPRX?

Does the media favor SVRA or CPRX?

Do analysts prefer SVRA or CPRX?

Which has better valuation and earnings, SVRA or CPRX?

Which has more volatility and risk, SVRA or CPRX?

Is SVRA or CPRX more profitable?

Summary

How does Savara compare to Kiniksa Pharmaceuticals International?

Do institutionals and insiders have more ownership in SVRA or KNSA?

Which has more risk & volatility, SVRA or KNSA?

Do analysts recommend SVRA or KNSA?

Is SVRA or KNSA more profitable?

Does the media favor SVRA or KNSA?

Which has stronger earnings & valuation, SVRA or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools